EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

BRAF mutations occur in 10–15% of colorectal cancers (CRCs) and confer adverse outcome. While RAF inhibitors such as vemurafenib (PLX4032) have proven effective in BRAF mutant melanoma, they are surprisingly ineffective in BRAF mutant CRCs, and the reason for this disparity remains unclear. Compared...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Corcoran, Ryan B., Ebi, Hiromichi, Turke, Alexa B., Coffee, Erin M., Nishino, Michiya, Cogdill, Alexandria P., Brown, Ronald D., Pelle, Patricia Della, Dias-Santagata, Dora, Hung, Kenneth E., Flaherty, Keith T., Piris, Adriano, Wargo, Jennifer A., Settleman, Jeffrey, Mino-Kenudson, Mari, Engelman, Jeffrey A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2012
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3308191/
https://ncbi.nlm.nih.gov/pubmed/22448344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-11-0341
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller